AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26209587 — intervention group
Group type: EXPERIMENTAL
Intervention: PG324 0.02%
Number of subjects: 298
Study 26209587 — intervention group
Group type: EXPERIMENTAL
Intervention: PG324 0.01%
Number of subjects: 298
Study 26209587 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 298
Study 26209587 — intervention group
Group type: COMPARATOR
Intervention: AR-13324 0.02%
Number of subjects: 298
Study 24769600 — intervention group
Group type: EXPERIMENTAL
Intervention: Procarbazine, lomustine, and vincristine (PCV) chemotherapy combined with standard radiation therapy (RT)
Number of subjects: 0
Study 24769600 — intervention group
Group type: COMPARATOR
Intervention: Standard course of radiation therapy (RT)
Number of subjects: 0
Study 22884055 — intervention group
Group type: EXPERIMENTAL
Intervention: Early PDT
Number of subjects: 119
Study 22884055 — intervention group
Group type: COMPARATOR
Intervention: Late PDT
Number of subjects: 119
Study 22884055 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 119
Study 20377116 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg once daily for 2 weeks
Number of subjects: 577
Study 20377116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577
Study 20377116 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 577
Study 17906931 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus intervention with a patient navigator
Number of subjects: 105
Study 17906931 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 105
Study 16359417 — intervention group
Group type: EXPERIMENTAL
Intervention: CPDA-1 RBC stored for up to 28 days
Number of subjects: 52
Study 16359417 — intervention group
Group type: COMPARATOR
Intervention: CPDA-1 RBC stored for up to 3 days
Number of subjects: 52
Study 12484804 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 100000
Study 10583351 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms kg‐1
Number of subjects: 180
Study 8923037 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticarcinogenic agent (specific agent not mentioned)
Number of subjects: 0
Study 8923037 — intervention group
Group type: COMPARATOR
Intervention: Controlled trial
Number of subjects: 0
Study 1909810 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone
Number of subjects: 80
Study 1909810 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral natural micronized progesterone
Number of subjects: 80
Study 6666842 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylmethacrylate
Number of subjects: 10
Study 6666842 — intervention group
Group type: COMPARATOR
Intervention: BDF cement
Number of subjects: 10
Study 30204734 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D replacement only (Group 2)
Number of subjects: 50
Study 30204734 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision and suturation after vitamin D replacement (Group 3)
Number of subjects: 50
Study 30204734 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group 1)
Number of subjects: 50
Study 28753838 — intervention group
Group type: EXPERIMENTAL
Intervention: pT3b-4, Gleason score ≥8, pN1 as independent predictors of prostate cancer-related death (PCRD)
Number of subjects: 2823
Study 28753838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-validation of the model
Number of subjects: 2823
Study 27938852 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (A)
Number of subjects: 26376
Study 27938852 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (L)
Number of subjects: 26376
Study 27938852 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (C)
Number of subjects: 26376
Study 24291151 — intervention group
Group type: EXPERIMENTAL
Intervention: ATLAS intervention (8-month multi-component school-based program)
Number of subjects: 0
Study 22466821 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume (V(T) 5 ml kg(‐1)) with high PEEP
Number of subjects: 88
Study 22466821 — intervention group
Group type: COMPARATOR
Intervention: Larger tidal volume (V(T) 8 ml kg(‐1)) with low PEEP
Number of subjects: 88
Study 20880345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin (E/S) + extended-release niacin (N)
Number of subjects: 1220
Study 20880345 — intervention group
Group type: COMPARATOR
Intervention: N
Number of subjects: 1220
Study 20880345 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe/simvastatin (E/S)
Number of subjects: 1220
Study 17659904 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle case management
Number of subjects: 147
Study 17659904 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 147
Study 16541972 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee venom extract
Number of subjects: 9
Study 14739714 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control strategy
Number of subjects: 1450
Study 14739714 — intervention group
Group type: COMPARATOR
Intervention: Rate control strategy
Number of subjects: 1450
Study 10515518 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week clinician-implemented language intervention program
Number of subjects: 21
Study 10515518 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment group (Control)
Number of subjects: 21
Study 8746601 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention
Number of subjects: 219
Study 8746601 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 219
Study 8746601 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Exercise intervention
Number of subjects: 219
Study 8746601 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 219
Study 8746601 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 219
Study 8746601 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides, HDL cholesterol, and insulin variables
Number of subjects: 219
Study 2042788 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) infusion (7 mg/kg bolus followed by 10 mg/kg/h continuous infusion)
Number of subjects: 17
Study 2042788 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (30 ng/kg/min)
Number of subjects: 17
Study 2042788 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 17
Study 2042788 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent MgSO4 and epinephrine administration
Number of subjects: 17
Study 7266894 — intervention group
Group type: EXPERIMENTAL
Intervention: E.N.L. protocol (erythromycin + neomycin + 600 mg lincomycin 1 hr prior to surgery)
Number of subjects: 30
Study 7266894 — intervention group
Group type: COMPARATOR
Intervention: E.N. protocol (erythromycin + neomycin)
Number of subjects: 30
Study 31552526 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (150 mg) administered as a single subcutaneous injection 2 weeks postoperatively.
Number of subjects: 20
Study 31552526 — intervention group
Group type: COMPARATOR
Intervention: Intranasal steroids (budesonide or mometasone furoate, 100 μg twice daily for 6 months) starting 2 weeks postoperatively.
Number of subjects: 20
Study 31418855 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 milligrams cobalt intravenously as CoCl2 weekly
Number of subjects: 8
Study 31418855 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 milligrams cobalt intravenously as CoCl2 weekly
Number of subjects: 8
Study 31418855 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 milligrams cobalt intravenously mid‐week and at the end of the week
Number of subjects: 8
Study 31418855 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cobalt administration)
Number of subjects: 8
Study 28560832 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) targeted to weight loss
Number of subjects: 264
Study 28560832 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE) control group
Number of subjects: 264
Study 26082975 — intervention group
Group type: EXPERIMENTAL
Intervention: Albu‐BChE (50, 100, and 300 mg)
Number of subjects: 0
Study 22948317 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cholecystectomy (PC)
Number of subjects: 130
Study 22948317 — intervention group
Group type: COMPARATOR
Intervention: Standard surgery (SS)
Number of subjects: 130
Study 22948317 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic cholecystectomy (PC) and Standard surgery (SS)
Number of subjects: 130
Study 22018363 — intervention group
Group type: EXPERIMENTAL
Intervention: Akreos Adapt Advanced Optics aspheric intraocular lens (IOL)
Number of subjects: 40
Study 22018363 — intervention group
Group type: COMPARATOR
Intervention: Sensar AR40e spherical acrylic IOL
Number of subjects: 40
Study 19455132 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 230
Study 19455132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 230
Study 16756038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous injections of 0.1 mL sterile water (n = 25)
Number of subjects: 50
Study 16756038 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline as placebo (n = 25)
Number of subjects: 50
Study 15116817 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic (total extraperitoneal approach, TEP)
Number of subjects: 261
Study 15116817 — intervention group
Group type: COMPARATOR
Intervention: Shouldice technique
Number of subjects: 261
Study 10780760 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone dipropionate (1.5 mg daily)
Number of subjects: 31
Study 10780760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9112304 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin
Number of subjects: 79
Study 9112304 — intervention group
Group type: COMPARATOR
Intervention: erythromycin
Number of subjects: 79
Study 7693425 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy consisting of fluorouracil, epirubicin plus cyclophosphamide (FEC) for 6 cycles
Number of subjects: 176
Study 7693425 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 176
Study 3513079 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced Salt Solution (BSS)
Number of subjects: 71
Study 3513079 — intervention group
Group type: EXPERIMENTAL
Intervention: BSS-Plus
Number of subjects: 71
Study 3513079 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral eye)
Number of subjects: 71
Study 3513079 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphakic and lensectomy eyes
Number of subjects: 71
Study 3513079 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 71
Study 3513079 — intervention group
Group type: EXPERIMENTAL
Intervention: BSS and BSS-Plus
Number of subjects: 71
Study 31927162 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Training plus Substance‐Education/12‐Steps (RT/SET)
Number of subjects: 199
Study 31927162 — intervention group
Group type: COMPARATOR
Intervention: Motivational Interviewing plus Cognitive Behavior Therapy (MI/CBT)
Number of subjects: 199
Study 31927162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 199
Study 30195996 — intervention group
Group type: COMPARATOR
Intervention: Intermittent sulfadoxine‐pyrimethamine (two doses of 1500 mg sulfadoxine and 75 mg pyrimethamine, 4 weeks apart)
Number of subjects: 900
Study 30195996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent chloroquine (two doses of 600 mg on day 1, 600 mg on day 2, and 300 mg on day 3)
Number of subjects: 900
Study 30195996 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis (600 mg on day 1 then 300 mg every week)
Number of subjects: 900
Study 27876265 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrupled hamstring tendon (HT) allograft
Number of subjects: 98
Study 27876265 — intervention group
Group type: COMPARATOR
Intervention: Doubled tibialis anterior (TA) allograft
Number of subjects: 98
Study 26276501 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg HDC
Number of subjects: 20
Study 26276501 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg HDC
Number of subjects: 20
Study 23855761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg
Number of subjects: 197
Study 23855761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg
Number of subjects: 197
Study 23855761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 15 mg
Number of subjects: 197
Study 23855761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 21442611 — intervention group
Group type: EXPERIMENTAL
Intervention: LOTUS™
Number of subjects: 18
Study 21442611 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Ace®
Number of subjects: 18
Study 21442611 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure™
Number of subjects: 18
Study 19250365 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire responses from nulliparae who declined RCT participation
Number of subjects: 107
Study 19250365 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire responses regarding autonomy
Number of subjects: 107
Study 19250365 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of midwife information
Number of subjects: 107
Study 16962881 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg per day
Number of subjects: 5584
Study 16962881 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg per day
Number of subjects: 5584
Study 16962881 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg and 80 mg (combined analysis)
Number of subjects: 5584
Study 15290426 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf compression device
Number of subjects: 10
Study 15290426 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar-calf sequential compression device
Number of subjects: 10
Study 11426356 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (n = 18)
Number of subjects: 33
Study 11426356 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia with intravenous morphine (n = 15)
Number of subjects: 33
Study 9429042 — intervention group
Group type: EXPERIMENTAL
Intervention: PRBC units transfused to survivors (median age 17 days, range 5-35)
Number of subjects: 31
Study 9429042 — intervention group
Group type: COMPARATOR
Intervention: PRBC units transfused to nonsurvivors (median age 25 days, range 9-36)
Number of subjects: 31
Study 9429042 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of PRBC age with mortality
Number of subjects: 31
Study 7868100 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum monitoring plus medication (either previously effective medication or nortriptyline)
Number of subjects: 23
Study 7868100 — intervention group
Group type: COMPARATOR
Intervention: Monitoring alone
Number of subjects: 23
Study 2508567 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C: MMC 12 mg/m2 i.v. at operation day and 6 mg/m2 in every 2 months + UFT 600 mg/day p.o.
Number of subjects: 1138
Study 2508567 — intervention group
Group type: COMPARATOR
Intervention: Regimen D: MMC 12 mg/m2 i.v. at operation day and 6 mg/m2 in every 2 months + UFT 400 mg/day p.o.
Number of subjects: 1138
Study 789082 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (up to 480 mg daily)
Number of subjects: 0
Study 789082 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (up to 600 mg daily)
Number of subjects: 0
Study 31701363 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus
Number of subjects: 2002
Study 31701363 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 2002
Study 31264764 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (LY2963016)
Number of subjects: 1249
Study 28744883 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubly robust estimator
Number of subjects: 0
Study 25205142 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1450
Study 25205142 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 1450
Study 25205142 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1450
Study 24133024 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal massager
Number of subjects: 95
Study 24133024 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (0.1% sodium hyaluronate solution, five times daily)
Number of subjects: 95
Study 22250936 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor Luncheon with family present
Number of subjects: 0
Study 22250936 — intervention group
Group type: COMPARATOR
Intervention: Luncheon with no donor family present
Number of subjects: 0
Study 20737130 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulsed diode laser with SHR (Super Hair Removal) mode
Number of subjects: 18
Study 20737130 — intervention group
Group type: COMPARATOR
Intervention: Long-pulsed alexandrite laser
Number of subjects: 18
Study 19075085 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from media
Number of subjects: 58
Study 19075085 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal support
Number of subjects: 58
Study 19075085 — intervention group
Group type: EXPERIMENTAL
Intervention: Community support
Number of subjects: 58
Study 19075085 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care team support
Number of subjects: 58
Study 19075085 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace support
Number of subjects: 58
Study 19075085 — intervention group
Group type: EXPERIMENTAL
Intervention: Family and friends support
Number of subjects: 58
Study 16116055 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (12 mg intravenously before reperfusion)
Number of subjects: 368
Study 16116055 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously before reperfusion)
Number of subjects: 368
Study 16116055 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 368
Study 16116055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study 14598999 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Risers 'Skills for Success' Program (CORE + FLEX)
Number of subjects: 327
Study 14598999 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Risers 'Skills for Success' Program (CORE + FLEX and CORE-only combined)
Number of subjects: 327
Study 14598999 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control condition
Number of subjects: 327
Study 10804076 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular doses of nortriptyline (60 mg-80 mg/day)
Number of subjects: 69
Study 10804076 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of nortriptyline (10 mg-13 mg/day)
Number of subjects: 69
Study 8960488 — intervention group
Group type: EXPERIMENTAL
Intervention: Polishing teeth
Number of subjects: 735
Study 8960488 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamental injection
Number of subjects: 735
Study 8960488 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber dam placement
Number of subjects: 735
Study 8960488 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix band with wedge placement
Number of subjects: 735
Study 8960488 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushing alone
Number of subjects: 735
Study 8507417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (160 mg trimethoprim and 800 mg sulphamethoxazole) twice a day on Mondays, Wednesdays and Fridays (n = 81)
Number of subjects: 166
Study 8507417 — intervention group
Group type: COMPARATOR
Intervention: Dapsone (100 mg) plus pyrimethamine (25 mg) once a week (n = 85)
Number of subjects: 166
Study 8507417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (TMP-SMX)
Number of subjects: 166
Study 8507417 — intervention group
Group type: COMPARATOR
Intervention: Dapsone plus pyrimethamine (DP)
Number of subjects: 166
Study 3541819 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride
Number of subjects: 0
Study 3541819 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine mesylate
Number of subjects: 0
Study 28731885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeper stretch daily for 8 weeks
Number of subjects: 37
Study 28731885 — intervention group
Group type: COMPARATOR
Intervention: Usual activities
Number of subjects: 37
Study 27265816 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking (six-week supervised group training once per week, followed by six weeks of independent Nordic walking 4 times a week for 30 minutes each session)
Number of subjects: 40
Study 27265816 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 40
Study 24403477 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg of elemental zinc/day for eight weeks)
Number of subjects: 17
Study 24403477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 21383341 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent ibuprofen (400 mg)
Number of subjects: 89
Study 21383341 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ibuprofen (Nurofen(®) 2 × 200 mg)
Number of subjects: 89
Study 21383341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 20730396 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartWave500 (HW)
Number of subjects: 120
Study 20730396 — intervention group
Group type: COMPARATOR
Intervention: Standard transtelephonic (TT) event recorder
Number of subjects: 120
Study 18427840 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy
Number of subjects: 239
Study 18427840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 16171715 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-frame GBPS
Number of subjects: 65
Study 16171715 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-frame GBPS
Number of subjects: 65
Study 12576370 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of epinephrine, 1.5 mg, in 4 mL of 3% saline solution (group 2; n = 27)
Number of subjects: 52
Study 12576370 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of epinephrine, 1.5 mg, in 4 mL of 0.9% saline solution (group 1; n = 25)
Number of subjects: 52